Compare Stocks → Elon Musk’s PRIME is Set to Shock the World (From InvestorPlace) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NYSE:BTXNASDAQ:CIDMNASDAQ:NLOKNYSE:VG Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBTXBrooklyn ImmunoTherapeutics$2.00-1.5%$2.23$0.17▼$10.10$117.65M4.61515,543 shs12,620 shsCIDMCinedigm$1.02-3.8%$1.15$0.27▼$0.79$190.65M2.05710,288 shs94,081 shsNLOKNortonLifeLock$25.03-1.0%$21.62$20.12▼$30.92$14.30B0.765.78 million shs6.62 million shsVGVonage$20.99$20.99$12.85▼$21.00$5.39BN/A4.39 million shs4,076 shs10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBTXBrooklyn ImmunoTherapeutics-1.48%-1.00%-6.98%+19.76%-29.12%CIDMCinedigm-3.77%+20.14%-17.41%-33.77%+101,999,900.00%NLOKNortonLifeLock-0.08%+6.69%+22.88%+17.18%+61.90%VGVonage0.00%0.00%0.00%0.00%0.00%Elon Musk’s PRIME is Set to Shock the World (Ad)Must-See: Elon's New Invention is Absolutely Insane When you click here and see what Elon Musk’s new invention does…You will NOT believe it. But Elon just tested this in a real human… And the result was mind-blowing.Click here for the full story…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBTXBrooklyn ImmunoTherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACIDMCinedigmN/AN/AN/AN/AN/AN/AN/AN/ANLOKNortonLifeLockN/AN/AN/AN/AN/AN/AN/AN/AVGVonageN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBTXBrooklyn ImmunoTherapeuticsN/AN/AN/AN/ACIDMCinedigmN/AN/AN/AN/ANLOKNortonLifeLockN/AN/AN/AN/AVGVonageN/AN/AN/AN/ASales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBTXBrooklyn ImmunoTherapeuticsN/AN/AN/AN/AN/AN/ACIDMCinedigm$72.33M2.64N/AN/AN/A∞NLOKNortonLifeLock$2.82B5.08N/AN/AN/A∞VGVonageN/AN/AN/AN/AN/AN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBTXBrooklyn ImmunoTherapeuticsN/A-$2.27N/A∞N/AN/AN/AN/AN/ACIDMCinedigmN/A-$0.05N/A∞N/AN/AN/AN/AN/ANLOKNortonLifeLockN/A$1.4317.50∞N/AN/AN/AN/AN/AVGVonageN/AN/A0.00∞N/AN/AN/AN/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBTXBrooklyn ImmunoTherapeuticsN/AN/AN/AN/AN/ACIDMCinedigmN/AN/AN/AN/AN/ANLOKNortonLifeLock$0.502.00%N/A34.97%N/AVGVonageN/AN/AN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipBTXBrooklyn ImmunoTherapeutics26.00%CIDMCinedigm8.03%NLOKNortonLifeLock94.86%VGVonageN/AInsider OwnershipCompanyInsider OwnershipBTXBrooklyn ImmunoTherapeutics20.50%CIDMCinedigm16.40%NLOKNortonLifeLock3.30%VGVonageN/AMiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBTXBrooklyn ImmunoTherapeuticsN/A58.83 millionN/ANo DataCIDMCinedigm140186.92 millionN/ANot OptionableNLOKNortonLifeLockN/A571.37 millionN/AOptionableVGVonageN/A256.58 millionN/AOptionableVG, NLOK, CIDM, and BTX HeadlinesRecent News About These CompaniesNovember 18, 2023 | consumeraffairs.comVonage ReviewsOctober 24, 2023 | businessnewsdaily.comRingCentral vs. Vonage: Comparison PageOctober 13, 2023 | businessnewsdaily.comVonage Review and Pricing PlansApril 19, 2023 | finance.yahoo.comVonage Meetings API Delivers Visual Engagement for an Enhanced Customer JourneyFebruary 22, 2023 | forbes.comOoma Office Vs. Vonage: Which One Is Best For You?January 25, 2023 | forbes.comBest Landline Home Phone Service Providers Of January 2023January 25, 2023 | tech.coVonage Review – Features, Pricing, Pros and ConsJanuary 14, 2023 | thestreet.comRealMoney Radio Recap: Bounce ScenariosJanuary 13, 2023 | thestreet.comVonage's Purchase of Nexmo Signals More Upside for SharesNovember 16, 2022 | finance.yahoo.comExamRoom.AI Relies on the Vonage Communications Platform to Power Remote Testing and Proctoring Services GloballySeptember 27, 2022 | finance.yahoo.comInvitation to briefing on Vonage and Global Network PlatformNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBrooklyn ImmunoTherapeuticsNYSE:BTXEterna Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B. The company is headquartered in San Diego, CA.CinedigmNASDAQ:CIDMCineverse Corp. is a global streaming technology and entertainment company. It owns and operates streaming channels, all powered by its advanced, proprietary technology platform. The firm currently features enthusiast brands for subscription video on demand (SVOD), advertising-based video on demand (AVOD), and free, ad-supported streaming television (FAST) channels. It entertains consumers around the globe by providing premium feature films and television series, enthusiast streaming channels, and technology services to some media, retail, and technology companies. The company was founded by A. Dale Mayo on March 31, 2000 and is headquartered in New York, NY.NortonLifeLockNASDAQ:NLOKGen Digital, Inc. engages in the provision of security, storage, and systems management solutions. The firm focuses on providing consumer cyber safety with its business solutions. The company was founded by Gary Hendrix in April 1982 and is headquartered in Tempe, AZ.VonageNYSE:VGVonage, a global cloud communications leader, helps businesses accelerate their digital transformation. Vonage's Communications Platform is fully programmable and allows for the integration of Video, Voice, Chat, Messaging and Verification into existing products, workflows and systems. Vonage's fully programmable unified communications and contact center applications are built from the Vonage platform and enable companies to transform how they communicate and operate from the office or anywhere, providing enormous flexibility and ensuring business continuity. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
